Esomeprazole, a major new drug in Laimei pharmaceutical industry, obtained GMP certificate

In the evening of April 1, Laimei pharmaceutical announced that the company received the GMP certificate issued by Chongqing food and drug administration, including esomeprazole API and capsule production line Esomeprazole is one of the heavyweight new drugs reserved by the pharmaceutical industry of Laimei The product was approved for production in August last year, and passing GMP certification is the last administrative link before the production and marketing of the product Esomeprazole is the latest generation of proton pump inhibitors The original research drug is AstraZeneca star drug "nexin" Its sales volume in 2010 and 2012 ranked first in the digestive prescription drugs in the United States According to the information on the website of the State Food and Drug Administration (CFDA), at present, only AstraZeneca and Laimei pharmaceutical are approved to produce Esomeprazole in China, and Laimei pharmaceutical products will share the domestic market with AstraZeneca after listing Laimei pharmaceutical is mainly engaged in the production and sales of anti infection, specialty and large infusion products In 2013, the company achieved an operating revenue of 759 million yuan.